PURE Bioscience to Announce Fourth Quarter and Fiscal 20...(c silver whichformulates well with other...)

Date:10/10/2008

c silver, which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at http://www.purebio.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Contact:

Paul G. Henning, Vice President

Cameron Associates

212 554 5462

paul@cameronassoc.com

'/>"/>

SOURCE PURE Bioscience Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related biology technology :

1. Pressure BioSciences, Inc. Provides Corporate Update
2. Isis Announces Award of Up to $8.4 Million in New Government Grants and Contracts to Its Ibis Biosciences Subsidiary for Pathogen Detection and Human Forensics
3. Dr. Charles Sanders to Become Lead Director of Epiphany Biosciences
4. Lumiphore Partners with Biophor Diagnostics, Inc. to Develop Tests for Drugs of Abuse; Appoints Ibis Biosciences Founder David J. Ecker to Board
5. Sangamo BioSciences to Present at Two Upcoming Investor Conferences
6. Nomad Bioscience: New Plant Biotechnology Company Founded to Focus on Biomaterials and Biopharmaceuticals
7. Nomad Bioscience Announces Broad License Agreement
8. LI-COR Biosciences Offers $1.75 Million in Matching Funds for Undergraduate Genomics Education
9. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
10. Tethys Bioscience Announces Acquisition of Lipomics Technologies
11. Ardea Biosciences to Present at the UBS Global Life Sciences Conference and the Third Annual JMP Securities Healthcare Focus Conference